An Uncontrolled, Open-label Phase IIb Trial of Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 20 Jan 2018
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- Sponsors Bayer
- 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium
- 05 Jan 2018 Status changed from active, no longer recruiting to completed.
- 01 Dec 2017 Planned End Date changed from 10 Nov 2017 to 11 Dec 2017.